



Nearly 7 billion
patient treatment days

with EU approved
biosimilar medicines
since 2006



The number of treatment
days with anti-TNF medicines
increased **X2**
from 2013-2023



€56 billion
cumulative savings
from the impact of biosimilar
competition since 2006,
€6 billion
in 2024 alone



A growing opportunity
for patients with over
110 new biologic
medicines opening to
biosimilar competition
by 2032



A considerable
opportunity for European
healthcare budget: a

€53.5Bn
market will open to
competition by 2032



By 2030,
1st cell & gene
therapies will open to
biosimilar competition



Biosimilar candidates are
under development for
1/3 of biologics
losing exclusivity by 2032



Biosimilar medicines
represent **4%** of the
total pharmaceutical
spending in Europe (<€10
billion)

Nearly 7 billion
patient treatment days
with EU approved
biosimilar medicines since
2006



Thanks to biosimilar
competition, **the number
of treatment days** with
anti- TNF medicines
increased **x2**
from 2013-2023



€56 billion
cumulative savings
from the impact of biosimilar
competition since 2006,
€6 billion
in 2024 alone



A growing opportunity
for patients with over
**110 new biologic
medicines** opening
to biosimilar
competition by 2032




A considerable opportunity
for European healthcare
budget: a **€53.5Bn**
market will **open to**
competition by 2032



By 2030,
**1st cell & gene
therapies** will open to
biosimilar competition



Biosimilar medicines
opportunity remains largely
untapped with only
12% volume share
of the accessible market in
Europe



Biosimilar medicines
represent **4%** of the
**total pharmaceutical
spending** in Europe
(<€10 billion)



Biosimilar candidates
are under development for
1/3 of biologics
losing exclusivity by 2032

